Trientine induced colitis during therapy for Wilson disease: A case report and review of the literature

BMC Pharmacology and Toxicology

Volumn 16, Issue 1, 2015, Pages

  Boga, Salih ^a   Jain, Dhanpat ^a   Schilsky, Michael L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colitis; Trientine; Wilson disease

Indexed keywords

ATROPINE PLUS DIPHENOXYLATE; ATYPICAL ANTIPSYCHOTIC AGENT; CIPROFLOXACIN; ESCITALOPRAM; LOPERAMIDE; OLANZAPINE; PENICILLAMINE; PREDNISONE; QUETIAPINE; TRIENTINE; ZINC; CHELATING AGENT;

ADULT; AGITATION; ARTICLE; BLOODY DIARRHEA; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLONOSCOPY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; ILEITIS; MAINTENANCE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCOLITIS; PEPTOCLOSTRIDIUM DIFFICILE; PSYCHOSIS; STOMACH MUCOSA INJURY; TREATMENT FAILURE; TRIENTINE INDUCED COLITIS; WILSON DISEASE; CHEMICALLY INDUCED; HEPATOLENTICULAR DEGENERATION; TREATMENT WITHDRAWAL;

ADULT; CHELATING AGENTS; COLITIS; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; TRIENTINE; WITHHOLDING TREATMENT;

EID: 84959175565     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/s40360-015-0031-z     Document Type: Article

References (11)

1. Scheinberg IH. Wilson's disease. J Rheumatol Suppl. 1981;7:90-3.
2. Waslhe JM. Management of penicillamine nephropathy in Wilson's disease: A new chelating agent. Lancet. 1969;2:1401-2.
3. Waslhe JM. Wilson's disease; new oral therapy. Lancet. 1956;270:25-6.
4. Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Eng J Med. 1987;317:209-13.
5. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012;56:671-85.
6. Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD), Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089-111.
7. Product Information. Syprine (trientine). Aton Pharma, Lawrenceville, NJ; 2013
8. Gibbs KR, Walshe JM. Orphan Diseases. In: Orphan Drugs JH, Scheimberg Walshe JM, editors. The Metabolism of Trientine: Animal Studies. Manchester, UK: Manchester University Press; 1986.
9. Dahlman T, Hartvig P, Löfholm M, Nordlinder H, Lööf L, Westermark K. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). Q J Med. 1995;88:609-16.
10. Członkowska A, Litwin T, Karlíski M, Dziezyc K, Chabik G, Czerska M. D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease. Eur J Neurol. 2014;21:599-606.
11. Wiernicka A, Jáczyk W, Dadalski M, Avsar Y, Schmidt H, Socha P. Gastrointestinal side effects in children with Wilson's disease treated with zinc sulphate. World J Gastroenterol. 2013;19:4356-62.